Based on 3 Wall Street analysts offering 12 month price targets for Marinus in the last 3 months. The average price target is $0.95 with a high forecast of $2.00 and a low forecast of $0.30. The average price target represents a 72.73% change from the last price of $0.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6523076923076924,0.7646153846153847,0.8769230769230769,0.9892307692307692,1.1015384615384616,1.2138461538461538,1.3261538461538462,1.4384615384615385,1.5507692307692307,1.6630769230769231,1.7753846153846153,1.8876923076923076,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5715384615384616,0.6030769230769231,0.6346153846153846,0.6661538461538461,0.6976923076923076,0.7292307692307692,0.7607692307692308,0.7923076923076923,0.8238461538461538,0.8553846153846153,0.8869230769230769,0.9184615384615384,{"y":0.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5215384615384616,0.5030769230769231,0.4846153846153846,0.46615384615384614,0.4476923076923077,0.42923076923076925,0.4107692307692308,0.3923076923076923,0.37384615384615383,0.35538461538461535,0.3369230769230769,0.31846153846153846,{"y":0.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.32,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.99,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.92,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$2.00

Average Price Target$0.95

Lowest Price Target$0.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

12/30/24

xxxxxxxxxxxxx

Douglas Tsao

H.C. Wainwright

Hold

263.64%

Upside

Reiterated

11/14/24

Valuation and Risks. Our Neutral rating and $2 price target for Marinus are based on 3x our 2035 risk-adjusted revenue estimate of $70M. We adjust each pipeline indication for the probability of success with CDD at 100% as a commercialized asset, RSE at 30% and LGS at 5%. We lowered our POS in TSC to 0% following the unsuccessful readout. Key risks include regulatory approval; commercial success; product concentration, as ganaxolone is the only product in Marinus' portfolio; competitors could develop superior products in the indications that Marinus is pursuing.

Andrew Tsai

Jefferies

$0.5→$0.3

Hold

-45.45%

Downside

Reiterated

11/14/24

Marinus Pharmaceuticals (MRNS) PT Lowered to $0.30 at JefferiesJefferies analyst Andrew Tsai lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $0.30 (from $0.50) while maintaining a Hold rating.

Charles Duncan

Cantor Fitzgerald

Buy

627.27%

Upside

Initiated

11/13/24

Marinus (MRNS) Initiated with a Buy at Cantor Fitzgerald

Brian Abrahams

RBC Capital

Hold

81.82%

Upside

Reiterated

11/12/24

RBC Capital Reaffirms Their Hold Rating on Marinus (MRNS)

Joseph Thome

TD Cowen

―

Hold

―

Reiterated

11/12/24

Analysts Offer Insights on Healthcare Companies: Marinus (NASDAQ: MRNS) and Medios AG (Other OTC: MEDOF)

Jay Olson

Oppenheimer

―

Buy

―

Reiterated

10/25/24

Analysts Offer Insights on Healthcare Companies: Integer Holdings (NYSE: ITGR), Marinus (NASDAQ: MRNS) and Community Health (NYSE: CYH)

Jason Kolbert

D. Boral Capital

$23→$3

Buy

445.45%

Upside

Reiterated

10/24/24

Marinus Pharmaceuticals price target lowered to $3 from $23 at EF HuttonMarinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/22/24

Buy Rating Affirmed for Marinus's Ganaxolone: Promising TSC Treatment Poised for Success

Michael Higgins

Ladenburg Thalmann & Co.

―

Hold

―

Reiterated

08/14/24

Maintaining Hold on Marinus Pharmaceuticals Amid Financial Uncertainty and Pipeline Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Marinus

Which Analyst Should I Follow If I Want to Buy MRNS and Sell After:

1 Month

xxx

Success Rate

6/12 ratings generated profit

Average Return

+5.88%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.88% per trade.

3 Months

xxx

Success Rate

7/12 ratings generated profit

Average Return

+15.78%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +15.78% per trade.

1 Year

Jay OlsonOppenheimer

Success Rate

5/12 ratings generated profit

Average Return

+5.37%

reiterated a buy rating 4 months ago

Copying Jay Olson's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +5.37% per trade.

2 Years

xxx

Success Rate

3/12 ratings generated profit

Average Return

-17.43%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -17.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNS Analyst Recommendation Trends

Rating

Sep 24

Oct 24

Nov 24

Dec 24

Jan 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRNS has received 1 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. MRNS average Analyst price target in the past 3 months is $0.95.

Each month's total comprises the sum of three months' worth of ratings.

MRNS Financial Forecast

MRNS Earnings Forecast

Next quarter’s earnings estimate for MRNS is -$0.33 with a range of -$0.38 to -$0.25. The previous quarter’s EPS was -$0.42. MRNS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.92% of the time in the same period. In the last calendar year MRNS has Preformed in-line its overall industry.

MRNS Sales Forecast

Next quarter’s sales forecast for MRNS is $10.81M with a range of $9.70M to $13.50M. The previous quarter’s sales results were $8.54M. MRNS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 45.83% of the time in the same period. In the last calendar year MRNS has Preformed in-line its overall industry.

MRNS Stock Forecast FAQ

What is MRNS’s average 12-month price target, according to analysts?

Based on analyst ratings, Marinus Pharmaceuticals Inc’s 12-month average price target is $0.95.

What is MRNS’s upside potential, based on the analysts’ average price target?

Marinus Pharmaceuticals Inc has 72.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRNS a Buy, Sell or Hold?

Marinus Pharmaceuticals Inc has a consensus rating of Hold which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.

What is Marinus Pharmaceuticals Inc’s price target?

The average price target for Marinus Pharmaceuticals Inc is $0.95. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $0.30. The average price target represents 72.73% Increase from the current price of $0.55.

What do analysts say about Marinus Pharmaceuticals Inc?

Marinus Pharmaceuticals Inc’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of MRNS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Marinus (MRNS) Stock Forecast & Price Target

MRNS Analyst Ratings

MRNS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Marinus

MRNS Analyst Recommendation Trends

MRNS Financial Forecast

MRNS Earnings Forecast

MRNS Sales Forecast

MRNS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts